🇺🇸 FDA
Pipeline program

GLPG5101

CP0201-NHL

Phase 2 gene_therapy active

Quick answer

GLPG5101 for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma is a Phase 2 program (gene_therapy) at Lakefront Biotherapeutics NV with 1 ClinicalTrials.gov record(s).

Program details

Company
Lakefront Biotherapeutics NV
Indication
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Phase
Phase 2
Modality
gene_therapy
Status
active

Clinical trials